Germano Geno J 4

What Happened

• Geno J. Germano, a director of Precision BioSciences, reported the vesting/conversion of 21,000 Restricted Stock Units (RSUs) into common shares on May 20, 2026. The Form 4 shows an acquisition of 21,000 shares (derivative conversion) and a matching disposition of 21,000 shares at $0.00. No cash proceeds or market sale is reported in the filing.

Key Details

• Transaction date: May 20, 2026; Form 4 filed: May 22, 2026 (report appears timely).
• Transactions reported as code M (exercise/conversion of a derivative): Acquired 21,000 shares (conversion of RSUs); Disposed 21,000 shares at $0.00 (derivative).
• Shares owned after the transaction: Not specified in the provided filing data.
• Footnotes: F1 — RSUs vested on May 20, 2026. F2 — Each RSU converts to one share of common stock. F3 — RSUs were granted June 3, 2025 and vested per the grant’s vesting schedule (earlier of June 3, 2026 or the day before the next annual meeting, subject to continued service).
• The filing does not explicitly state the reason for the $0.00 disposition; filings that show an acquisition and a simultaneous $0.00 disposition often reflect share withholding for taxes or internal transfers, but the Form 4 here does not specify.

Context

• This is an award/vesting event (RSU conversion) rather than an open-market purchase or sale. Such vesting disclosures document compensation being converted into stock for insiders and do not necessarily indicate a buy or sell decision by the insider. Transaction code M is used to report conversion/exercise of a derivative (here, RSUs converting into shares).